APE/REF1 inhibitors for the treatment of cancer

US12128015B2 · kind B2 · utility

Assignees

• Chapman University · US
• The Regents of the University of California · US

Inventors

• Sun Yang · Lake Forest, US
• Keykavous Parang · Irvine, US
• Richard Chamberlin · Towanda, US
• Frank L. Meyskens, Jr. · Irvine, US

Key dates

• Filing date: Nov 18, 2022
• Grant date: Oct 29, 2024
• Expiry date: Nov 18, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Apurinic/apuyrimidinic endonuclease 1/Redox Factor-1 (APE/Ref-1) inhibitors are provided along with methods of using the same. The inhibitor has the structure of Formula I: or a pharmaceutically acceptable salt thereof. n is an integer from 4 to 14, X and X′ are each independently H or OH, and Y and Y′ are each independently H or OH.